Benutzerspezifische Werkzeuge

Lungenkarzinom

NSCLC: ICT01-101

A first-in-human, two-part, open-label, clinical study to assess the saftey, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/ refractory cancer (EVICTION ...Mehr…

NSCLC: Novartis CLXH254X2102

A Phase Ib, open-label, multicenter study of oral LXH254-centric combinations in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer or NRAS mutant melanoma.Mehr…

NSCLC: Novartis CDKY709A12101

A phase I/Ib, open-label, multi-center, study of DKY709 as a single agent and in combination with PDR001 in patients with advanced solid tumors.Mehr…

NSCLC: Find

A phase II trial to evaluate efficacy and safety of erdafitinib in patients with advanced NSCLC harboring FGFR genetic alterations after relapse of standard therapy.Mehr…

NSCLC: Boehringer Ingelheim 1438-0001

A First–in-human Phase I, non-randomized, open-label, multi-center dose escalation trial of BI 764532 administered by repeated intravenous infusions in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3.Mehr…